#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright Â© 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Dysregulation of Inflammasome Priming and Activation by MicroRNAs in Human Immune-Mediated Diseases."
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Yojana Gadiya"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/conso
# --------------------------------------------------------
 DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
 DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/4aa36980578c7d2cff07371abf768f15db89cd11/export/conso-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
 DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
 DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
 DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
 DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns"
 DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns"
# DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
 DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
 DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
 DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
# DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
 DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
 DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"
 DEFINE NAMESPACE NCIT           AS PATTERN "^C\d+$"
 DEFINE NAMESPACE OMIT           AS PATTERN "^\d{7}$"
 DEFINE NAMESPACE BTO            AS PATTERN "^\d{7}$"
###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
 DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
 DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
 DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
 DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
 DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
# DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
 DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
 DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "30962309"}

SET Evidence = "Inflammasomes are endogenous multimeric protein complexes that mediate the cleavage of proinflammatory cytokines, especially IL-1beta and IL-18, in response to a diverse set of stimuli such as infections, tissue damage, and metabolic imbalances (1, 2)."
path(MESH:Infection) -> complex(MESH:Inflammasomes)
#tissue damage
path(NCIT:C50773) -> complex(MESH:Inflammasomes)
path(MESH:Metabolome) -> complex(MESH:Inflammasomes)
complex(MESH:Inflammasomes) -> deg(p(HGNC:IL1B))
complex(MESH:Inflammasomes) -> deg(p(HGNC:IL18))

SET Evidence = "Mutations in genes encoding the inflammasome sensor molecules NLRP3 and pyrin cause
autoinflammatory disorders involving an excessive activation of innate immune responses, namely cryopyrin-associated periodic syndrome and familial Mediterranean fever (3)."
g(HGNC:NLRP3) -> complex(MESH:Inflammasomes)
g(HGNC:MEFV) -> complex(MESH:Inflammasomes)
#cryopyrin-associated periodic syndrome
p(HGNC:NLRP3, var("?")) -> path(NCIT:C84657)
p(HGNC:MEFV, var("?")) -> path(NCIT:C84657)
p(HGNC:NLRP3, var("?")) -> path(DOID:"familial Mediterranean fever")
p(HGNC:MEFV, var("?")) -> path(DOID:"familial Mediterranean fever")
path(NCIT:C84657) => bp(GO:"activation of innate immune response")
path(DOID:"familial Mediterranean fever") => bp(GO:"activation of innate immune response")
#Autoinflammatory Syndrome/disorder
path(NCIT:C84657) isA path(NCIT:C119050)
path(DOID:"familial Mediterranean fever") isA path(NCIT:C119050)

SET Evidence = "Moreover, changes in inflammasome activity and closely related dysregulation of IL-1beta and IL-18 expression levels have been linked to cancer (4) and various human disorders involving autoimmune processes, such as multiple sclerosis (MS) (5) and rheumatic diseases (6)."
act(complex(MESH:Inflammasomes)) -- path(DOID:cancer)
g(HGNC:IL1B) -- path(DOID:cancer)
p(HGNC:IL18) -- path(DOID:cancer)
act(complex(MESH:Inflammasomes)) -- path(DOID:"multiple sclerosis")
g(HGNC:IL1B) -- path(DOID:"multiple sclerosis")
p(HGNC:IL18) -- path(DOID:"multiple sclerosis")
act(complex(MESH:Inflammasomes)) -- path(DOID:"rheumatic disease")
g(HGNC:IL1B) -- path(DOID:"rheumatic disease")
p(HGNC:IL18) -- path(DOID:"rheumatic disease")
path(DOID:"rheumatic disease") -- path(MESH:Autoimmunity)
path(DOID:"multiple sclerosis") -- path(MESH:Autoimmunity)

SET Evidence = "Several miRNAs can target mRNA transcripts of genes coding for components of inflammasome complexes
or for regulators of the inflammasomes."
r(MESH:MicroRNAs) reg complex(MESH:Inflammasomes)

SET Evidence = "The common function of the canonical inflammasomes is the proteolytic activation of IL-1beta and IL-18 and their secretion (2)"
#canonical inflammasomes - NLRP1, NLRP3, NLRC4, AIM2, and pyrin subunits
p(HGNC:NLRP1) -> act(p(HGNC:IL1B))
p(HGNC:NLRP1) -> sec(p(HGNC:IL1B))
p(HGNC:NLRP3) -> act(p(HGNC:IL1B))
p(HGNC:NLRP3) -> sec(p(HGNC:IL1B))
p(HGNC:NLRC4) -> act(p(HGNC:IL1B))
p(HGNC:NLRC4) -> sec(p(HGNC:IL1B))
p(HGNC:AIM2) -> act(p(HGNC:IL1B))
p(HGNC:AIM2) -> sec(p(HGNC:IL1B))
p(HGNC:MEFV) -> act(p(HGNC:IL1B))
p(HGNC:MEFV) -> sec(p(HGNC:IL1B))

p(HGNC:NLRP1) -> act(p(HGNC:IL18))
p(HGNC:NLRP1) -> sec(p(HGNC:IL18))
p(HGNC:NLRP3) -> act(p(HGNC:IL18))
p(HGNC:NLRP3) -> sec(p(HGNC:IL18))
p(HGNC:NLRC4) -> act(p(HGNC:IL18))
p(HGNC:NLRC4) -> sec(p(HGNC:IL18))
p(HGNC:AIM2) -> act(p(HGNC:IL18))
p(HGNC:AIM2) -> sec(p(HGNC:IL18))
p(HGNC:MEFV) -> act(p(HGNC:IL18))
p(HGNC:MEFV) -> sec(p(HGNC:IL18))

SET Evidence = "Noncanonical inflammasomes have been proposed to realize additional functions such as the mediation of programmed cell death (pyroptosis) and the initiation of NLRP3 assembly (8, 9)."
#noncanonical inflammasomes - caspase-4, caspase-5, and caspase-8
p(HGNC:CASP4) -> path(MESH:Pyroptosis)
p(HGNC:CASP4) -> bp(GO:"NLRP3 inflammasome complex assembly")
p(HGNC:CASP5) -> path(MESH:Pyroptosis)
p(HGNC:CASP5) -> bp(GO:"NLRP3 inflammasome complex assembly")
p(HGNC:CASP8) -> path(MESH:Pyroptosis)
p(HGNC:CASP8) -> bp(GO:"NLRP3 inflammasome complex assembly")

SET Evidence = "Moreover, the inflammasomes control the microbiome in humans, both by hindering invasion of pathogens and by regulating the composition of commensal bacteria (10)."
complex(MESH:Inflammasomes) reg path(MESH:Microbiota)
complex(MESH:Inflammasomes) =| path(MESH:"Host-Pathogen Interactions")

SET Evidence = "In mouse models, deficiency of inflammasome components enhances the susceptibility to inflammatory bowel diseases (IBD) (10)."
SET Species = "10090"
complex(MESH:Inflammasomes) =| path(DOID:"inflammatory bowel disease")
UNSET Species

SET Evidence = "Furthermore, several therapies that are currently in use to treat autoimmune disorders, such as IFN-beta and glatiramer acetate in MS, glucocorticoids in systemic lupus erythematosus (SLE), and the TNF-alpha inhibitor infliximab in rheumatic diseases, partially affect the regulation of inflammasomes (11â14)."
a(PUBCHEM:223370366) -| path(DOID:"multiple sclerosis")
a(PUBCHEM:3081884) -| path(DOID:"multiple sclerosis")
a(PUBCHEM:223370366) reg complex(MESH:Inflammasomes)
a(PUBCHEM:3081884) reg complex(MESH:Inflammasomes)

a(PUBCHEM:53787563) -| path(DOID:"systemic lupus erythematosus")
a(PUBCHEM:53787563) reg complex(MESH:Inflammasomes)

a(PUBCHEM:135305802) -| path(DOID:"rheumatic disease")
a(PUBCHEM:135305802) =| p(HGNC:TNF)
a(PUBCHEM:135305802) reg complex(MESH:Inflammasomes)

SET Evidence = "It is composed of the sensor molecule NLRP3, the adapter protein ASC that enhances complex formation, and of proâcaspase-1."
#It - NLRP3 inflammasome
#PYCARD - ASC
complex(GO:"NLRP3 inflammasome complex") hasComponents list(p(HGNC:NLRP3), p(HGNC:PYCARD), p(HGNC:CASP1))

SET Evidence = "Upon assembly, the activated inflammasome converts proâcaspase-1 into caspase-1, which cleaves proâIL-1b and proâIL-18 into mature proinflammatory cytokines IL-1b and IL-18 (15). The proinflammatory cytokines are then secreted (16)."
act(complex(GO:"NLRP3 inflammasome complex")) -> sec(p(HGNC:IL1B))
act(complex(GO:"NLRP3 inflammasome complex")) -> sec(p(HGNC:IL18))

SET Evidence = "In the brain, and in particular the microglia, NLRP3 mRNA levels are among the highest throughout human tissues (18, 19)."
a(MESH:Brain) -> r(HGNC:NLRP3, loc(MESH:Microglia))

SET Evidence = "For example, the miRNAs miR-20b-5p, miR-30a-5p, and miR-146a-5p are dysregulated in immunological and neurologic pathways in MS (22), and the miRNA levels in peripheral blood cells of MS patients change in response to IFN-beta treatment (23)."
SET MeSHDisease = "Multiple Sclerosis"
m(MIRBASE:"hsa-mir-20a") -- a(MESH:"Neural Pathways")
m(MIRBASE:"hsa-mir-20a") -- a(MESH:"Immune System")
m(MIRBASE:"hsa-mir-30a") -- a(MESH:"Neural Pathways")
m(MIRBASE:"hsa-mir-30a") -- a(MESH:"Immune System")
m(MIRBASE:"hsa-mir-146a") -- a(MESH:"Neural Pathways")
m(MIRBASE:"hsa-mir-146a") -- a(MESH:"Immune System")
SET Cell = "blood cell"
a(PUBCHEM:223370366) reg m(MIRBASE:"hsa-mir-20a")
a(PUBCHEM:223370366) reg m(MIRBASE:"hsa-mir-30a")
a(PUBCHEM:223370366) reg m(MIRBASE:"hsa-mir-146a")
UNSET Cell
UNSET MeSHDisease

SET Evidence = "The first step of canonical miRNA biogenesis is transcription into primary miRNAs (pri-miRNAs) by RNA polymerase II (24, 25)."
act(p(MESH:"RNA Polymerase II"), ma(GO:"rRNA transcription")) -> r(NCIT:C25967)

SET Evidence = "In a two-step process, the primiRNA is first cleaved into a precursor miRNA by Drosha/
DGCR8 and additional RNA-binding proteins, translocated into the cytoplasm by exportin-5, and subsequently processed
by Dicer/TRBP to form a short miRNA duplex (26â28)."
p(HGNC:DGCR8) -> m(NCIT:C25967, frag("?"))
p(HGNC:DROSHA) -> m(NCIT:C25967, frag("?"))
m(NCIT:C25967, frag("?")) -> r(MESH:MicroRNAs)
p(HGNC:XPO5) -> p(MESH:"RNA-Binding Proteins", loc(GO:cytoplasm))
composite(p(MESH:"RNA-Binding Proteins"), p(HGNC:DICER1)) -> complex(p(MESH:MicroRNAs), p(MESH:MicroRNAs))
composite(p(MESH:"RNA-Binding Proteins"), p(HGNC:NCOA6)) -> complex(p(MESH:MicroRNAs), p(MESH:MicroRNAs))

SET Evidence = "The resulting duplex is incorporated into an Argonaute protein and unwound so that only one strand (i.e., the mature miRNA) is kept in the RNA-induced silencing complex, which targets transcripts with matching sequences for degradation and prevents translation into proteins (25, 29, 30)."
composite(p(MESH:MicroRNAs), p(MESH:MicroRNAs), p(HGNCGENEFAMILY:"Argonaute/PIWI family")) -> composite(p(MESH:MicroRNAs), p(HGNCGENEFAMILY:"Argonaute/PIWI family"))
composite(p(MESH:MicroRNAs), p(HGNCGENEFAMILY:"Argonaute/PIWI family")) =| path(MESH:"RNA Stability")
composite(p(MESH:MicroRNAs), p(HGNCGENEFAMILY:"Argonaute/PIWI family")) =| bp(GO:translation)


########Coding help
SET Evidence = "Pairing of the miRNA seed region (nucleotides at position 2â7 from the 59 end) and complementary sites preferably within 39 untranslated regions (39 UTRs) of target mRNAs mediates translational repression and destabilization of the bound transcripts (34)."



SET Evidence = "In humans, mRNA destabilization by deadenylation and subsequent exonucleolytic decay dominates
the regulatory effect of miRNAs, whereas the contribution from direct translational repression is relatively small
(35â39)."
SET Species = "9606"
p(MESH:MicroRNAs) =| bp(GO:"mRNA polyadenylation")
bp(GO:"mRNA polyadenylation") -- path(MESH:"RNA Stability")
p(MESH:MicroRNAs) =| path(MESH:"RNA Stability")
p(MESH:MicroRNAs) => bp(GO:"exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-independent decay")
p(MESH:MicroRNAs) =| bp(GO:translation)
UNSET Species

SET Evidence = "In 2012, two studies that were published in The Journal of Immunology identified miR-223-3p as the first human miRNA directly targeting NLRP3 (47, 48)."
m(MIRBASE:"hsa-mir-223") -- p(HGNC:NLRP3)

SET Evidence = "A role for this interaction in the differentiation of monocytes to macrophages was proposed, as miR-223-3p levels decrease during differentiation, whereas NLRP3 protein levels increase (47)."
bp(GO:"monocyte differentiation") -| m(MIRBASE:"hsa-mir-223")
bp(GO:"monocyte differentiation") -> p(HGNC:NLRP3)

SET Evidence = "NLRP3 mRNA levels correlate negatively with miR-223-3p expression in myeloid cells (48)."
SET Cell = "myeloid cell"
r(HGNC:NLRP3) neg m(MIRBASE:"hsa-mir-223")
UNSET Cell


###coding help
SET Evidence = "Interestingly, among human innate immune cells, miR-223-3p expression is highest in neutrophils
and lowest in dendritic cells (48)."

SET Evidence = "Moreover, a miRNA from EBV, a common virus that targets B cells and is considered essential for
the development of the neurodegenerative disease MS (49), ebvmiR-BART15-3p, regulates NLRP3 expression (47)."
m(MIRBASE:"ebv-mir-BART15") reg p(HGNC:NLRP3)
m(MIRBASE:"ebv-mir-BART15") -> path(DOID:"multiple sclerosis")

SET Evidence = "Infected B cells can secrete ebv-miR-BART15-3p via exosomes and inhibit NLRP3 activity in noninfected cells, which may be a mechanism for the virus to evade host defense (47)."
SET MeSHAnatomy = "B-Lymphocytes"
composite(m(MIRBASE:"ebv-mir-BART15"), a(MESH:"B-Lymphocytes")) =| p(HGNC:NLRP3)
p(HGNC:NLRP3) => bp(GO:"evasion or tolerance of host defenses by virus")
UNSET MeSHAnatomy

SET Evidence = "Interestingly, miR-223-3p and ebv-miR-BART15-3p hybridize with NLRP3 mRNA at the same site, and a common polymorphism, rs10802501, is present in the target site and could influence the binding of both miRNAs (47)."
g(DBSNP:rs10802501) reg composite(m(MIRBASE:"hsa-mir-223"), m(MIRBASE:"ebv-mir-BART15"), r(HGNC:NLRP3))

SET Evidence = "Among them are miR-7-5p and miR-30e-5p, and treatment with mimics of these miRNAs alleviates Parkinson disease (PD)-like phenotypes in mouse models involving accumulation of alpha-synuclein (50â52)."
SET Species = "10090"
m(MIRBASE:"hsa-mir-7-1") => p(CONSO:"alpha-synuclein aggregates")
m(MIRBASE:"hsa-mir-30e") => p(CONSO:"alpha-synuclein aggregates")
p(CONSO:"alpha-synuclein aggregates") -- path(DOID:"Parkinson's disease")
UNSET Species

SET Evidence = "The NLRP3 inflammasome and IL-1beta production can be activated by alpha-synuclein, which drives neurodegeneration (53)."
p(HGNC:SNCA) -> act(complex(GO:"NLRP3 inflammasome complex"))
p(HGNC:SNCA) -> act(p(HGNC:IL1B)))
p(HGNC:SNCA) -> path(DOID:"neurodegenerative disease")
act(complex(GO:"NLRP3 inflammasome complex")) -> path(DOID:"neurodegenerative disease")
act(p(HGNC:IL1B)) -> path(DOID:"neurodegenerative disease")

SET Evidence = "NLRP3 is also a direct target of miR-20b-5p, upregulation of which alleviates Mycobacterium tuberculosisâinduced inflammation in murine lung tissue (54)."
m(MIRBASE:"hsa-mir-20b") reg act(p(HGNC:NLRP3))
SET Species = "10090"
SET Anatomy = "lung"
SET MeSHDisease = "Mycobacterium Infections"
m(MIRBASE:"hsa-mir-20b") => path(MESH:Inflammation)
UNSET MeSHDisease
UNSET Anatomy
UNSET Species

SET Evidence = "Additionally, miR-22-3p downregulates NLRP3 expression, and this miRNA is decreased in injured coronary arterial endothelial cells in a rat model of high-fat dietâinduced coronary heart disease, whereas upregulation of miR-22-3p exerts a protective effect on cell survival (55)."
m(MIRBASE:"hsa-mir-22") -| r(HGNC:NLRP3)
SET Species = "10114"
path(DOID:"coronary artery disease") neg m(MIRBASE:"hsa-mir-22")
UNSET Species
m(MIRBASE:"hsa-mir-22") pos path(MESH:"Cell Survival")

SET Evidence = "The expression of miR-133b-3p, which also targets NLRP3, is reduced in the nasal mucosa of a mouse model of allergic rhinitis (56)."
m(MIRBASE:"hsa-mir-133b") -- r(HGNC:NLRP3)

SET Species = "10090"

SET MeSHAnatomy = "Nasal Mucosa"

path(DOID:"allergic rhinitis") -| m(MIRBASE:"hsa-mir-133b")

SET Evidence = "Allergic symptoms of the mice, immune cell infiltration, cytokine levels, and NLRP3 inflammasome protein expression were reduced in the nasal mucosa after administration of modified miR-133b-3p mimics, indicating that miR-133b-3p downregulation may contribute to the pathogenesis of allergic rhinitis, whereas its upregulation shows therapeutic potential (56)."
path(DOID:"allergic rhinitis") -| path(HP:"Myocardial immune cell infiltration")
path(DOID:"allergic rhinitis") -| a(MESH:Cytokines)
path(DOID:"allergic rhinitis") -| complex(GO:"NLRP3 inflammasome complex")
m(MIRBASE:"hsa-mir-133b") -| path(DOID:"allergic rhinitis")

UNSET MeSHAnatomy

SET Evidence = "In a mouse model of prosopalgia, miR-186-5p is downregulated, and injection of miRNA mimics could alleviate neuropathic pain behavior by downregulating NLRP3 expression and NLRP3 inflammasome activity (57)."
#trigeminal neuralgia - prosopalgia
#Neuralgia - neuropathic pain
path(DOID:"trigeminal neuralgia") -| m(MIRBASE:"hsa-mir-186")
r(HGNC:NLRP3) neg path(MESH:Neuralgia)
act(complex(GO:"NLRP3 inflammasome complex")) neg path(MESH:Neuralgia)

SET Evidence = "The levels of miR-495-3p are decreased in mice with myocardial ischemia/reperfusion injury, and
by targeting NLRP3, treatment with miR-495-3p mimics alleviates inflammation (58)"
path(DOID:"myocardial infarction") -| m(MIRBASE:"hsa-mir-495")
path(EFO:"ischemia reperfusion injury") -| m(MIRBASE:"hsa-mir-495")
composite(m(MIRBASE:"hsa-mir-495"), r(HGNC:NLRP3)) -> path(MESH:Inflammation)

UNSET Species


SET Evidence = "In human epithelial cells, overexpression of miR-214-3p downregulates caspase-1, and the miRNA is downregulated in cataract lens anterior capsular tissues (59)."
SET Species = "9606"
SET Cell = "epithelial cell"
m(MIRBASE:"hsa-mir-214") -| p(HGNC:CASP1)
UNSET Cell
path(HP:"Anterior cortical cataract") =| m(MIRBASE:"hsa-mir-214")
UNSET Species

SET Evidence = "MiR-371a-5p, miR-373-3p, and miR-543-3p have been proposed to enhance TNF-alphaâinduced cell death
by targeting the noncanonical caspase-8 inflammasome, and they are overexpressed in hepatocellular carcinoma tissue (60)."
m(MIRBASE:"hsa-mir-371a") -- p(HGNC:CASP8, loc(GO:"inflammasome complex"))
m(MIRBASE:"hsa-mir-373") -- p(HGNC:CASP8, loc(GO:"inflammasome complex"))
m(MIRBASE:"hsa-mir-543") -- p(HGNC:CASP8, loc(GO:"inflammasome complex"))
p(HGNC:CASP8, loc(GO:"inflammasome complex")) -> p(HGNC:TNF)
p(HGNC:TNF) -> bp(GO:"cell death")
path(DOID:"hepatocellular carcinoma") => m(MIRBASE:"hsa-mir-371a")
path(DOID:"hepatocellular carcinoma") => m(MIRBASE:"hsa-mir-373")
path(DOID:"hepatocellular carcinoma") => m(MIRBASE:"hsa-mir-543")

SET Evidence = "Caspase-11, the murine ortholog of human caspase-4 and caspase-5, was shown to be indirectly regulated by miR-34a, miR-451, and miR-874 (61)."
m(MIRBASE:"hsa-mir-34a") reg p(HGNC:CASP4)
m(MIRBASE:"hsa-mir-34a") reg p(HGNC:CASP5)
m(MIRBASE:"hsa-mir-451a") reg p(HGNC:CASP4)
m(MIRBASE:"hsa-mir-451a") reg p(HGNC:CASP5)
m(MIRBASE:"hsa-mir-874") reg p(HGNC:CASP4)
m(MIRBASE:"hsa-mir-874") reg p(HGNC:CASP5)

SET Evidence = "Several miRNAs negatively regulate the NF-kappaBâmediated priming of the NLRP3 inflammasome by targeting a wide range of transducers of TLR, IL-1R, and TNFR signaling."
#Figure 1
#OMIT:0016854 - NF-kappaB
m(MIRBASE:"hsa-mir-34c") neg p(OMIT:0016854)
m(MIRBASE:"hsa-mir-146a") neg p(OMIT:0016854)
m(MIRBASE:"hsa-mir-155") neg p(OMIT:0016854)
m(MIRBASE:"hsa-mir-302b") neg p(OMIT:0016854)
m(MIRBASE:"hsa-mir-330") neg p(OMIT:0016854)
p(HGNCGENEFAMILY:"Toll like receptors") -> p(OMIT:0016854)
m(MIRBASE:"hsa-mir-34c") -| p(HGNCGENEFAMILY:"Toll like receptors")
m(MIRBASE:"hsa-mir-146a") -| p(HGNCGENEFAMILY:"Toll like receptors")
m(MIRBASE:"hsa-mir-155") -| p(HGNCGENEFAMILY:"Toll like receptors")
m(MIRBASE:"hsa-mir-302b") -| p(HGNCGENEFAMILY:"Toll like receptors")
p(HGNC:IL1R1) -> p(OMIT:0016854)
m(MIRBASE:"hsa-mir-34c") -| p(HGNC:IL1R1)
m(MIRBASE:"hsa-mir-146a") -| p(HGNC:IL1R1)
m(MIRBASE:"hsa-mir-155") -| p(HGNC:IL1R1)
m(MIRBASE:"hsa-mir-302b") -| p(HGNC:IL1R1)
p(HGNCGENEFAMILY:"Tumor necrosis factor receptor superfamily") -> p(OMIT:0016854)
m(MIRBASE:"hsa-mir-330") -| p(HGNCGENEFAMILY:"Tumor necrosis factor receptor superfamily")
p(OMIT:0016854) -> r(HGNC:NLRP3)
p(OMIT:0016854) -> r(HGNC:IL1B))

SET Evidence = "Signals from both TLR4 and IL-1R are transduced via MyD88, IRAK1, and IRAK4, TRAF6, IKK, and finally NF-kappa B, which then induces NLRP3 and proâIL-1b transcription (2, 62)."
p(HGNC:TLR4) -> p(HGNC:MYD88)
p(HGNC:MYD88) -> p(HGNC:IRAK1)
p(HGNC:IRAK1) -> p(OMIT:0016854)
p(HGNC:IL1R1) -> p(HGNC:IRAK4)
p(HGNC:IRAK4) -> p(HGNC:TRAF6)
p(HGNC:TRAF6) -> p(HGNCGENEFAMILY:"IKK complex")
p(HGNCGENEFAMILY:"IKK complex") -> p(OMIT:0016854)

SET Evidence = "In a study on inflammation of gout, miR-302b-3p was upregulated after induction of THP-1âderived macrophages using monosodium urate (MSU)."
SET CellLine = "THP-1"
SET MeSHDisease = "Gout"
a(CHEBI:"monosodium urate") -> a(MESH:Macrophages)
a(MESH:Macrophages) -> m(MIRBASE:"hsa-mir-302b")
UNSET MeSHDisease
UNSET CellLine

SET Evidence = "Overexpression of miR-302b-3p directly downregulates IRAK4 and thereby inhibits NLRP3
expression (63)."
m(MIRBASE:"hsa-mir-302b") =| p(HGNC:IRAK4)
p(HGNC:IRAK4) => r(HGNC:NLRP3)
m(MIRBASE:"hsa-mir-302b") =| r(HGNC:NLRP3)

SET Species = "10090"

SET Evidence = "The mRNA and protein expression of TRAF6, IRAK1 and downstream NLRP3, ASC, and caspase-1 were upregulated in MSU-induced bone marrowâderived macrophages of miR-146a-5p knockout mice as compared with wild-type
mice."
SET Cell = "bone marrow macrophage"
m(MIRBASE:"hsa-mir-146a") -| p(HGNC:TRAF6)
m(MIRBASE:"hsa-mir-146a") -| p(HGNC:IRAK1)
m(MIRBASE:"hsa-mir-146a") -| r(HGNC:TRAF6)
m(MIRBASE:"hsa-mir-146a") -| r(HGNC:IRAK1)
p(HGNC:TRAF6) -> r(HGNC:NLRP3)
p(HGNC:TRAF6) -> r(HGNC:PYCARD)
p(HGNC:TRAF6) -> r(HGNC:CASP1)
p(HGNC:TRAF6) -> p(HGNC:NLRP3)
p(HGNC:TRAF6) -> p(HGNC:PYCARD)
p(HGNC:TRAF6) -> p(HGNC:CASP1)

p(HGNC:IRAK1) -> r(HGNC:NLRP3)
p(HGNC:IRAK1) -> r(HGNC:PYCARD)
p(HGNC:IRAK1) -> r(HGNC:CASP1)
p(HGNC:IRAK1) -> p(HGNC:NLRP3)
p(HGNC:IRAK1) -> p(HGNC:PYCARD)
p(HGNC:IRAK1) -> p(HGNC:CASP1)
m(MIRBASE:"hsa-mir-146a") -| p(HGNC:NLRP3)
m(MIRBASE:"hsa-mir-146a") -| r(HGNC:NLRP3)
m(MIRBASE:"hsa-mir-146a") -| p(HGNC:PYCARD)
m(MIRBASE:"hsa-mir-146a") -| r(HGNC:PYCARD)
m(MIRBASE:"hsa-mir-146a") -| p(HGNC:CASP1)
m(MIRBASE:"hsa-mir-146a") -| r(HGNC:CASP1)
UNSET Cell

SET Evidence = "The miR-146a-5pâdeficient mice developed a more severe phenotype of gouty arthritis (64)."
#OMIT:0016001 - gouty arthritis
m(MIRBASE:"hsa-mir-146a") =| path(OMIT:0016001)

UNSET Species

SET Evidence = "MyD88 is downregulated by miR-155-5p overexpression in rat prefrontal cortex, and this alleviates depressive-like behaviors (65), and IKK gamma (gene symbol: IKBKG) expression is reduced by miR-34c-5p."
SET Species = "10114"
SET MeSHAnatomy = "Prefrontal Cortex"
m(MIRBASE:"hsa-mir-155") -| p(HGNC:MYD88)
p(HGNC:MYD88) -| path(MESH:Depression)
m(MIRBASE:"hsa-mir-34c") -| r(HGNC:IKBKG)
UNSET MeSHAnatomy
UNSET Species

SET Evidence = "In response to stimulation with damage-associated molecular patterns, miR-34c-5p is highly expressed in PBMC (66). Through this mechanism, miR-34c-5p was proposed to limit aberrant sterile acute or chronic inflammation
(66)."
#Damage-Associated Molecular Pattern Molecule - NCIT:C118474
#NCIT:C12954 - PBMC
path(NCIT:C118474) => m(MIRBASE:"hsa-mir-34c", loc(NCIT:C12954))
m(MIRBASE:"hsa-mir-34c") neg path(EFO:"induces sterile inflammation")
m(MIRBASE:"hsa-mir-34c") -| path(MESH:Inflammation)

SET Evidence = "IL-1R2, a receptor that inhibits IL-1 signaling in a competitive manner (67), is downregulated by miR-383-3p (68)."
p(HGNC:IL1R2) =| bp(GO:"interleukin-1-mediated signaling pathway")
m(MIRBASE:"hsa-mir-383") -| p(HGNC:IL1R2)

SET Species = "10114"

SET Evidence = "In myocardial tissues of a rat model of atherosclerosis, miR-383-3p levels are reduced, whereas IL-1R2 expression is increased."
SET Anatomy = "myocardial layer"
path(DOID:atherosclerosis) -| m(MIRBASE:"hsa-mir-383")
path(DOID:atherosclerosis) -> p(HGNC:IL1R2)
UNSET Anatomy

SET Evidence = "Overexpression of miR-383-3p decreases the protein levels of caspase-1 and the secretion of IL-1beta and IL-18 in homocysteine induced endothelial injury in rat coronary arteries (68)."
SET Cell = "endothelial cell of coronary artery"
a(CHEBI:homocysteine) -> path(EFO:"endothelial dysfunction")
path(EFO:"endothelial dysfunction") => m(MIRBASE:"hsa-mir-383")
m(MIRBASE:"hsa-mir-383") -| p(HGNC:CASP1)
m(MIRBASE:"hsa-mir-383") -| sec(p(HGNC:IL1B))
m(MIRBASE:"hsa-mir-383") -| sec(p(HGNC:IL18))

UNSET Species

SET Evidence = "Binding of TNF-alpha to TNFRSF1A followed by downstream TRAF2/SphK1/S1P signaling constitutes another NF-kappa Bâactivating and NLRP3 inflammasome-priming pathway (69)."
composite(p(HGNC:TNF), p(HGNC:TNFRSF1A)) -> p(HGNC:TRAF2)
p(HGNC:TRAF2) -> p(HGNC:SPHK1)
p(HGNC:SPHK1) -> bp(GO:"sphingosine-1-phosphate receptor signaling pathway")
bp(GO:"sphingosine-1-phosphate receptor signaling pathway") -> act(p(OMIT:0016854))
bp(GO:"sphingosine-1-phosphate receptor signaling pathway") -> r(HGNC:NLRP3)


####how to encode for second part
SET Evidence = "Administration of miR-330-3p mimics attenuates fructose induced upregulation of SphK1, NF-kB, NLRP3, proâIL-1b, and IL-1b protein levels, whereas miR-330-3p inhibition has the opposite effect in a proximal tubule epithelial cell line from adult human kidney (HK-2 cells) (70)."
a(CHEBI:fructose) -> bp(GO:"sphingosine-1-phosphate receptor signaling pathway")
a(CHEBI:fructose) -> r(HGNC:NLRP3)
a(CHEBI:fructose) -> r(HGNC:IL1B)
a(CHEBI:fructose) -> p(HGNC:IL1B)
m(MIRBASE:"hsa-mir-330") -|  r(HGNC:NLRP3)
m(MIRBASE:"hsa-mir-330") -|  r(HGNC:IL1B)
m(MIRBASE:"hsa-mir-330") -|  p(HGNC:IL1B)

SET Evidence = "By targeting SphK1, miR-330-3p thus inhibits inflammasome priming (70)."
m(MIRBASE:"hsa-mir-330") -| bp(GO:"sphingosine-1-phosphate receptor signaling pathway")
bp(GO:"sphingosine-1-phosphate receptor signaling pathway") -> r(HGNC:NLRP3)
m(MIRBASE:"hsa-mir-330") -| r(HGNC:NLRP3)

SET Evidence = "The receptor IFNAR responds to IFN-alpha and IFN-beta and activates the JAK/STAT/ISGF3 pathway, which is able to drive NLRP3 expression (71)."
p(HGNC:IFNAR1) -- a(PUBCHEM:223370366)
p(HGNC:IFNAR1) -- a(NCIT:C20494)
p(HGNC:IFNAR1) -> bp(GO:"receptor signaling pathway via JAK-STAT")
p(HGNC:IFNAR1) -> act(complex(GO:"ISGF3 complex"))
bp(GO:"receptor signaling pathway via JAK-STAT") -> r(HGNC:NLRP3)
act(complex(GO:"ISGF3 complex")) -> r(HGNC:NLRP3)
p(HGNC:IFNAR1) -> r(HGNC:NLRP3)

SET Species = "9606"

SET Evidence = "JAK1 is targeted by miR-9-5p, and this miRNA is increased in human primary peripheral
blood monocytes stimulated with oxidized low density lipoproteins indicating its role as a regulator of inflammation (72, 73)."
SET Cell = "peripheral blood mononuclear cell"
m(MIRBASE:"hsa-mir-9-1") -| p(HGNC:JAK1)
a(CHEBI:"oxidised LDL") -> m(MIRBASE:"hsa-mir-9-1")
m(MIRBASE:"hsa-mir-9-1") reg path(MESH:Inflammation)
UNSET Cell

SET Evidence = "Overexpression of miR-9-5p inhibits NLRP3 inflammasome priming in atherosclerosis inflammation models using human THP-1âderived macrophages and primary peripheral blood
monocytes (72)"
SET CellLine = "THP-1"
SET MeSHDisease = "Atherosclerosis"
SET Cell = {"peripheral blood mononuclear cell", "macrophage"}
m(MIRBASE:"hsa-mir-9-1") =|  r(HGNC:NLRP3)
UNSET Cell
UNSET MeSHDisease
UNSET CellLine

UNSET Species

SET Evidence = "During mitochondrial stress, excessive reactive oxygen species (ROS), which can be reduced by superoxide dismutases (SOD), are generated, and they induce TXNIP, an NLRP3-activating factor (74)"
#SOD1/2 - from figure
SET CellStructure = "Mitochondria"
path(MESH:"Oxidative Stress") -> a(CHEBI:"reactive oxygen species")
UNSET CellStructure
a(CHEBI:"reactive oxygen species") -> p(HGNC:TXNIP)
p(HGNC:TXNIP) -> p(HGNC:NLRP3)
p(HGNC:SOD1) -| a(CHEBI:"reactive oxygen species")
p(HGNC:SOD2) -| a(CHEBI:"reactive oxygen species")

SET Evidence = "Fructose induces miR-377-3p expression in kidney cortex and glomeruli of rats as well as in a mouse podocyte cell line (75)."
SET Species = "10114"
SET MeSHAnatomy = {"Kidney Cortex", "Kidney Glomerulus"}
a(CHEBI:fructose) -> m(MIRBASE:"hsa-mir-377")
UNSET MeSHAnatomy
UNSET Species

SET Species = "10090"
SET MeSHAnatomy = "Podocytes"

a(CHEBI:fructose) -> m(MIRBASE:"hsa-mir-377")

SET Evidence = "Upregulation of miR-377-3p can inhibit SOD1 and SOD2 protein levels and thereby raise ROS levels and induce elevated NLRP3, ASC, caspase, and supernatant IL-1 beta protein levels in cultured mouse podocytes, implying a role for miR-377-3p in metabolic syndrome (75)."
m(MIRBASE:"hsa-mir-377") -| p(HGNC:SOD1)
m(MIRBASE:"hsa-mir-377") -| p(HGNC:SOD2)
m(MIRBASE:"hsa-mir-377") -> a(CHEBI:"reactive oxygen species")
a(CHEBI:"reactive oxygen species") -> p(HGNC:NLRP3)
a(CHEBI:"reactive oxygen species") -> p(HGNC:PYCARD)
a(CHEBI:"reactive oxygen species") -> p(HGNC:CASP1)
a(CHEBI:"reactive oxygen species") -> p(HGNC:IL1B)
m(MIRBASE:"hsa-mir-377") -> p(HGNC:NLRP3)
m(MIRBASE:"hsa-mir-377") -> p(HGNC:PYCARD)
m(MIRBASE:"hsa-mir-377") -> p(HGNC:CASP1)
m(MIRBASE:"hsa-mir-377") -> p(HGNC:IL1B)
m(MIRBASE:"hsa-mir-377") -- path(EFO:"metabolic syndrome")

UNSET MeSHAnatomy
UNSET Species

SET Evidence = "The NLRP3-activating factor TXNIP is inhibited by several individual miRNAs."
#figure 1
m(MIRBASE:"hsa-mir-17") -| p(HGNC:TXNIP)
m(MIRBASE:"hsa-mir-20a") -| p(HGNC:TXNIP)
m(MIRBASE:"hsa-mir-148a") -| p(HGNC:TXNIP)

SET Evidence = "Expression levels of miR-17-5p in rat brains and rat insulin-producing cells with endoplasmic reticulum stress (76, 77), of miR-20a-5p in rat fibroblast-like synoviocytes in adjuvant induced arthritis (78), and of miR-148a-3p in mouse hepatocytes in alcoholic hepatitis (79) are decreased and correlate
with upregulation of TXNIP and activation of the NLRP3 inflammasome."
SET Species = "10114"

SET MeSHAnatomy = {"Insulin-Secreting Cells", "Brain"}
path(EFO:"Endoplasmic Reticulum Stress") -| m(MIRBASE:"hsa-mir-17")
path(EFO:"Endoplasmic Reticulum Stress") -> p(HGNC:TXNIP)
m(MIRBASE:"hsa-mir-17") -| p(HGNC:TXNIP)
m(MIRBASE:"hsa-mir-17") -| p(HGNC:NLRP3)
UNSET MeSHAnatomy
SET MeSHAnatomy = "Synoviocytes"
path(EFO:arthritis) -| m(MIRBASE:"hsa-mir-20a")
path(EFO:arthritis) -> p(HGNC:TXNIP)
m(MIRBASE:"hsa-mir-20a") -| p(HGNC:TXNIP)
m(MIRBASE:"hsa-mir-20a") -| p(HGNC:NLRP3)
UNSET MeSHAnatomy

UNSET Species

SET Species = "10090"

SET Cell = "hepatocyte"
path(DOID:"alcoholic hepatitis") -| m(MIRBASE:"hsa-mir-148a")
path(DOID:"alcoholic hepatitis") -> p(HGNC:TXNIP)
m(MIRBASE:"hsa-mir-148a") -| p(HGNC:TXNIP)
m(MIRBASE:"hsa-mir-148a") -| p(HGNC:NLRP3)
UNSET Cell

UNSET Species
p(HGNC:TXNIP) -> p(HGNC:NLRP3)

SET Evidence = "The chemokine receptor CXCR4 was proposed to stabilize TXNIP (80)."
p(HGNC:CXCR4) -> p(HGNC:TXNIP)

SET Evidence = "In mice with sciatic nerve injury, overexpression of miR-23a-3p downregulates CXCR4, inhibits
the activation of the NLRP3 inflammasome and subsequent IL-1beta secretion, and alleviates neuropathic pain behavior (80)."
SET Species = "10090"
SET MeSHDisease = "Sciatic Neuropathy"
m(MIRBASE:"hsa-mir-23a") -| p(HGNC:CXCR4)
m(MIRBASE:"hsa-mir-23a") -| complex(GO:"NLRP3 inflammasome complex")
m(MIRBASE:"hsa-mir-23a") -| sec(p(HGNC:IL1B))
m(MIRBASE:"hsa-mir-23a")  -> path(MESH:Neuralgia)
UNSET MeSHDisease
UNSET Species
p(HGNC:CXCR4) -> complex(GO:"NLRP3 inflammasome complex")
complex(GO:"NLRP3 inflammasome complex") -> sec(p(HGNC:IL1B))

SET Evidence = "In an atherosclerosis model of human aortic endothelial cells treated with oxidized low density lipoproteins, miR-30c-5p is downregulated, leading to the upregulation of FOXO3 (81)."
SET Species = "9606"
SET MeSHDisease = "Atherosclerosis"
SET MeSHAnatomy = "Aorta"
composite(a(CHEBI:"oxidised LDL"), a(MESH:"Endothelial Cells")) -| m(MIRBASE:"hsa-mir-30c-1")
composite(a(CHEBI:"oxidised LDL"), a(MESH:"Endothelial Cells")) -> p(HGNC:FOXO3)
m(MIRBASE:"hsa-mir-30c-1") -| p(HGNC:FOXO3)
UNSET MeSHAnatomy
UNSET MeSHDisease
UNSET Species

SET Evidence = "The administration of miR-30c-5p mimics decreases FOXO3 expression, and the knockdown of FOXO3
downregulates NLRP3, caspase-1, and IL-1beta mRNA and protein levels, indicating a protective effect of the miRNA (81)."
m(MIRBASE:"hsa-mir-30c-1") -| r(HGNC:FOXO3)
r(HGNC:FOXO3) -> r(HGNC:NLRP3)
r(HGNC:FOXO3) -> p(HGNC:NLRP3)
r(HGNC:FOXO3) -> r(HGNC:CASP1)
r(HGNC:FOXO3) -> p(HGNC:CASP1)
r(HGNC:FOXO3) -> r(HGNC:IL1B)
r(HGNC:FOXO3) -> p(HGNC:IL1B)


#####how to code for promoter region? and hypermethylation?
SET Evidence = "The promotor of miR-145a-5p can be hypermethylated during atherosclerotic plaque formation, which leads to a decreased expression of miR-145a-5p, an upregulation of its target genes CD137 and NFATc1, and this induces the activation of the NLRP3 inflammasome."
#NCIT:C78739 - atherosclerotic plaque
path(NCIT:C78739) -> m(MIRBASE:"hsa-mir-145")
m(MIRBASE:"hsa-mir-145") -| m(MIRBASE:"hsa-mir-145")
m(MIRBASE:"hsa-mir-145") -> g(HGNC:TNFRSF9)
m(MIRBASE:"hsa-mir-145") -> g(HGNC:NFATC1)
m(MIRBASE:"hsa-mir-145") -> act(complex(GO:"NLRP3 inflammasome complex"))
g(HGNC:TNFRSF9) -> act(complex(GO:"NLRP3 inflammasome complex"))
g(HGNC:NFATC1) -> act(complex(GO:"NLRP3 inflammasome complex"))

m(MIRBASE:"hsa-mir-145") -| g(HGNC:TNFRSF9)
m(MIRBASE:"hsa-mir-145") -| g(HGNC:NFATC1)
m(MIRBASE:"hsa-mir-145") -| act(complex(GO:"NLRP3 inflammasome complex"))

SET Evidence = "Of the described miRNAs, miR-9-5p (83) and miR-155-5p (84) also directly target NFKB1 mRNA, and miR-7-5p (85) downregulates RELA expression. Both are subunits of NF-kappa B."
m(MIRBASE:"hsa-mir-9-1") -| r(HGNC:NFKB1)
m(MIRBASE:"hsa-mir-155") -| r(HGNC:NFKB1)
m(MIRBASE:"hsa-mir-7-1") -| r(HGNC:RELA)
complex(p(OMIT:0016854)) hasComponents list(p(HGNC:NFKB1), p(HGNC:RELA))

SET Evidence = "The most prominent roles for inflammasome-regulating miRNAs in autoimmune diseases
have been demonstrated for miR-146a-5p, miR-155-5p, and miR-223-3p, all of which are dysregulated in RA,MS, and SLE."
m(MIRBASE:"hsa-mir-146a") reg complex(MESH:Inflammasomes)
m(MIRBASE:"hsa-mir-155") reg complex(MESH:Inflammasomes)
m(MIRBASE:"hsa-mir-223") reg complex(MESH:Inflammasomes)
path(DOID:"rheumatoid arthritis") neg m(MIRBASE:"hsa-mir-146a")
path(DOID:"multiple sclerosis") neg m(MIRBASE:"hsa-mir-146a")
path(DOID:"systemic lupus erythematosus") neg m(MIRBASE:"hsa-mir-146a")
path(DOID:"rheumatoid arthritis") neg m(MIRBASE:"hsa-mir-155")
path(DOID:"multiple sclerosis") neg m(MIRBASE:"hsa-mir-155")
path(DOID:"systemic lupus erythematosus") neg m(MIRBASE:"hsa-mir-155")
path(DOID:"rheumatoid arthritis") neg m(MIRBASE:"hsa-mir-223")
path(DOID:"multiple sclerosis") neg m(MIRBASE:"hsa-mir-223")
path(DOID:"systemic lupus erythematosus") neg m(MIRBASE:"hsa-mir-223")

SET Evidence = "In PBMCs of patients with the immune-mediated neurodegenerative disease relapsing-remitting MS (RRMS), miR-146a-5p levels are increased compared with healthy controls, and treatment with glatiramer acetate partially restores miR-146a-5p expression to lower levels again (86, 87)."
SET Cell = "peripheral blood mononuclear cell"
path(DOID:"relapsing-remitting multiple sclerosis") => m(MIRBASE:"hsa-mir-146a")
a(PUBCHEM:3081884) -| m(MIRBASE:"hsa-mir-146a")
UNSET Cell


#####how to code for C allele part?
SET Evidence = "Interestingly, the C allele of the single-nucleotide polymorphism (SNP) rs2910164 in the
sequence encoding mir-146a is associated with an increased expression of this miRNA and release of proinflammatory cytokines in patients with RRMS, and in females, rs2910164 was proposed to alter MS susceptibility (88)."


SET Evidence = "Furthermore, miR-155-5p is expressed more strongly in peripheral blood monocytes and active brain lesions of MS patients than in healthy controls (87, 89)."
SET Cell = "peripheral blood mononuclear cell"
SET MeSHAnatomy = "Brain"
path(DOID:"multiple sclerosis") => m(MIRBASE:"hsa-mir-155")
UNSET MeSHAnatomy
UNSET Cell

SET Evidence = "Enhanced miRNA levels have been demonstrated for miR-22-3p in plasma of MS patients (90) and for miR-9-5p in circulating leukocytes of RRMS patients (91)."
path(DOID:"multiple sclerosis") => m(MIRBASE:"hsa-mir-22", loc(MESH:Plasma))
path(DOID:"relapsing-remitting multiple sclerosis") => m(MIRBASE:"hsa-mir-9-1", loc(MESH:"Leukocytes, Mononuclear"))

SET Evidence = "Other miRNAs are decreased in MS patient serum (e.g., miR-23a-3p and miR-223-3p in primary progressive MS) (92)."
path(DOID:"primary progressive multiple sclerosis") =| m(MIRBASE:"hsa-mir-23a")
path(DOID:"primary progressive multiple sclerosis") =| m(MIRBASE:"hsa-mir-223")

#######T allele coding
SET Evidence = "The T allele of SNP rs1044165 located near the sequence encoding mir-223 is associated with a higher risk of developing MS (93)."



SET Evidence = "Furthermore, in RRMS, miR-214 levels are downregulated in T cells in patients in the relapsing phase compared with patients in the remitting phase and healthy controls (94)."
SET MeSHAnatomy = "T-Lymphocytes"
path(DOID:"relapsing-remitting multiple sclerosis") -| m(MIRBASE:"hsa-mir-214")
UNSET MeSHAnatomy

SET Evidence = "In response to treatment of RRMS patients with natalizumab, the expression of miR-17-5p in T cells is decreased in comparison with untreated patients, and during relapse, miR-17-5p is upregulated
(95)."
a(PUBCHEM:135314782) -| path(DOID:"relapsing-remitting multiple sclerosis")
a(PUBCHEM:135314782) -| m(MIRBASE:"hsa-mir-17")
path(DOID:"relapsing-remitting multiple sclerosis") -> m(MIRBASE:"hsa-mir-17")

SET Evidence = "In case of miR-7-5p and miR-20b-5p, expression is upregulated in T cells during natalizumab treatment (96)."
SET MeSHAnatomy = "T-Lymphocytes"
a(PUBCHEM:135314782) => m(MIRBASE:"hsa-mir-7-1")
a(PUBCHEM:135314782) => m(MIRBASE:"hsa-mir-20b")
UNSET MeSHAnatomy

SET Evidence = "In RA, miR-22-3p levels are reduced in synovial tissue from RA patients compared with osteoarthritis patients (97), and low expression of miR-22-3p is associated with a good response
to adalimumab treatment (98)."
SET Cell = "synovial cell"
path(DOID:"rheumatoid arthritis") =| m(MIRBASE:"hsa-mir-22")
path(DOID:osteoarthritis) -| m(MIRBASE:"hsa-mir-22")
a(PUBCHEM:135335742) =| path(DOID:"rheumatoid arthritis")
a(PUBCHEM:135335742) => m(MIRBASE:"hsa-mir-22")
UNSET Cell

SET Evidence = "Furthermore, the expression of miR-9-5p is decreased in plasma of RA patients compared with healthy controls (99)."
path(DOID:"rheumatoid arthritis") =| m(MIRBASE:"hsa-mir-9-1", loc(MESH:Plasma))

SET Evidence = "The three miRNAs miR-223 (100), miR-155-5p (101), and miR-146a (102) are upregulated in
synovial tissue from RA patients compared with osteoarthritis synovium, and two of them, miR-155-5p and miR-146a-5p, are elevated in PBMCs of RA patients (103, 104)."
SET Cell = "synovial cell"
path(DOID:"rheumatoid arthritis") => m(MIRBASE:"hsa-mir-223")
path(DOID:"rheumatoid arthritis") => m(MIRBASE:"hsa-mir-155")
path(DOID:"rheumatoid arthritis") => m(MIRBASE:"hsa-mir-146a")
path(DOID:osteoarthritis) cnc m(MIRBASE:"hsa-mir-223")
path(DOID:osteoarthritis) cnc m(MIRBASE:"hsa-mir-155")
path(DOID:osteoarthritis) cnc m(MIRBASE:"hsa-mir-146a")
UNSET Cell
SET Cell = "peripheral blood mononuclear cell"
path(DOID:"rheumatoid arthritis") => m(MIRBASE:"hsa-mir-155")
path(DOID:"rheumatoid arthritis") => m(MIRBASE:"hsa-mir-146a")
UNSET Cell

SET Evidence = "Moreover, miR-223-3p is overexpressed in T cells, and miR-223-3p expression correlates with the titer of rheumatoid factor in patients with RA (105)."
path(DOID:"rheumatoid arthritis") => m(MIRBASE:"hsa-mir-223", loc(MESH:"T-Lymphocytes"))
m(MIRBASE:"hsa-mir-223") pos p(MESH:"Rheumatoid Factor")

SET Evidence = "Of interest, levels of miR-146a-5p are reduced in regulatory T cells of RA patients with active
disease and correlate with joint inflammation (106)."
path(DOID:"rheumatoid arthritis") =| m(MIRBASE:"hsa-mir-146a", loc(MESH:"T-Lymphocytes, Regulatory"))
m(MIRBASE:"hsa-mir-146a", loc(MESH:"T-Lymphocytes, Regulatory")) -- path(DOID:arthritis)


#######how to code?
SET Evidence = "Furthermore, the rs2910164 genotype GG in the sequence encoding mir-146a is associated with an increased risk of developing RA in females, whereas the CC genotype is related to a decreased disease severity in females and an increased disease severity in males (107)."


SET Evidence = "In patients with SLE, miR-155-5p expression is decreased in PBMCs compared with healthy controls (108)."
path(DOID:"systemic lupus erythematosus") =| m(MIRBASE:"hsa-mir-155", loc(MESH:"Peripheral Blood Stem Cells"))

SET Evidence = "In SLE urine, miR-155-5p levels are significantly higher, treatment with calcitriol reduces miR-155-5p levels, and miR-155-5p levels correlate with proteinuria and disease activity, whereas the amount of miR-146a-5p correlates with the estimated glomerular filtration rate in SLE patients (108)."
path(DOID:"systemic lupus erythematosus") => m(MIRBASE:"hsa-mir-155", loc(MESH:Urine))
a(PUBCHEM:5280453) =| m(MIRBASE:"hsa-mir-155")
m(MIRBASE:"hsa-mir-155") -- path(DOID:proteinuria)
SET Disease = "systemic lupus erythematosus"
m(MIRBASE:"hsa-mir-146a") -- bp(GO:"glomerular filtration")
UNSET Disease

SET Evidence = "In response to treatment with mycophenolic acid, miR-146a-5p levels are increased in T cells of patients versus untreated patients (109)."
#for SLE
a(CHEBI:"mycophenolic acid") -| path(DOID:"systemic lupus erythematosus")
a(CHEBI:"mycophenolic acid") -> m(MIRBASE:"hsa-mir-146a", loc(MESH:"T-Lymphocytes"))

SET Evidence = "Additionally, two SNPs upstream of the genome locus encoding mir-146a, rs57095329 and rs2431697, are associated with the miRNA expression level and with SLE development (110, 111)."
g(DBSNP:rs57095329) reg m(MIRBASE:"hsa-mir-146a")
g(DBSNP:rs57095329) -- path(DOID:"systemic lupus erythematosus")
g(DBSNP:rs2431697) reg m(MIRBASE:"hsa-mir-146a")
g(DBSNP:rs2431697) -- path(DOID:"systemic lupus erythematosus")

SET Evidence = "Several inflammasome-regulating miRNAs are downregulated in SLE: miR-223-3p in naive B cells of SLE patients (112), miR-20a-5p in monocytes (113), and miR-17-5p in PBMCs of adult (114) and pediatric SLE patients (115)"
path(DOID:"systemic lupus erythematosus") =| m(MIRBASE:"hsa-mir-223", loc(MESH:"B-Lymphocytes"))
path(DOID:"systemic lupus erythematosus") =| m(MIRBASE:"hsa-mir-20a", loc(MESH:Monocytes))
path(DOID:"systemic lupus erythematosus") =| m(MIRBASE:"hsa-mir-17", loc(MESH:"Peripheral Blood Stem Cells"))
m(MIRBASE:"hsa-mir-223") reg complex(MESH:Inflammasomes)
m(MIRBASE:"hsa-mir-20a") reg complex(MESH:Inflammasomes)
m(MIRBASE:"hsa-mir-17") reg complex(MESH:Inflammasomes)

SET Evidence = "A common manifestation of SLE, higher levels of miR-146a in glomeruli and miR-148a-3p in serum and glomeruli of patients with lupus nephritis have been reported relative to healthy controls (117, 118)."
SET Cell = "glomerular cell"
path(DOID:"systemic lupus erythematosus") => m(MIRBASE:"hsa-mir-146a")
UNSET Cell
SET MeSHAnatomy = {"Glomerular Basement Membrane", "Serum"}
path(DOID:"lupus nephritis") => m(MIRBASE:"hsa-mir-148a")
UNSET MeSHAnatomy

SET Evidence = "The levels of miR-23a-3p are elevated in the blood of patients with Crohn disease in comparison with healthy controls (120)"
path(DOID:"Crohn's disease") => m(MIRBASE:"hsa-mir-23a")

SET Evidence = "Furthermore, miR-146a expression is increased in colonic mucosa of Crohn disease patients compared with
ulcerative colitis and healthy controls, and it is increased in colonic tissue in both Crohn disease and ulcerative colitis (121)."
#colonic mucosa
path(DOID:"Crohn's disease") => m(MIRBASE:"hsa-mir-146a", loc(BTO:0000271))
path(DOID:"ulcerative colitis") cnc m(MIRBASE:"hsa-mir-146a", loc(BTO:0000271))
#colonic tissue
path(DOID:"ulcerative colitis") => m(MIRBASE:"hsa-mir-146a", loc(BTO:0001709))
path(DOID:"Crohn's disease") => m(MIRBASE:"hsa-mir-146a", loc(BTO:0001709))

SET Evidence = "The expression level of miR-7-5p is decreased in the serum of patients with PD (52)."
SET MeSHAnatomy = "Serum"
path(DOID:"Parkinson's disease") =| m(MIRBASE:"hsa-mir-7-1")
UNSET MeSHAnatomy

SET Evidence = "Moreover, miR-22-3p is downregulated in whole blood of newly diagnosed and in treated PD patients compared with healthy controls (126), and miR-34c-3p is downregulated in brain areas of PD patients with neuropathological lesions (127)."
path(DOID:"Parkinson's disease") => m(MIRBASE:"hsa-mir-22", loc(GO:"blood microparticle"))
SET MeSHAnatomy = "Brain"
SET MeSHDisease = "Parkinson Disease"
path(MESH:Neuropathology) =| m(MIRBASE:"hsa-mir-34c")
